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Progressive renal failure often complicates Fabry disease, the
pathogenesis of which is not well understood. To further
explore this we applied unbiased stereological quantitative
methods to electron microscopic changes of Fabry
nephropathy and the relationship between parameters of
glomerular structure and renal function in 14 young Fabry
patients (median age 12 years). Renal biopsies were obtained
shortly before enzyme replacement therapy from these
patients and from nine normal living kidney donors as
controls. Podocyte globotriaosylceramide (GL-3) inclusion
volume density increased progressively with age; however,
there were no significant relationships between age and
endothelial or mesangial inclusion volume densities. Foot
process width, greater in male Fabry patients, also
progressively increased with age compared with the controls,
and correlated directly with proteinuria. In comparison to the
biopsies of the controls, endothelial fenestration was reduced
in Fabry patients. Thus, our study found relationships
between quantitative parameters of glomerular structure in
Fabry nephropathy and age, as well as urinary protein
excretion. Hence, podocyte injury may play a pivotal role in
the development and progression of Fabry nephropathy.
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Reduced or absent activity of the lysosomal enzyme
a-galactosidase A in Fabry disease leads to accumulation of
its substrates, primarily globotriaosylceramide (GL-3), result-
ing in characteristic multilamellar lysosomal inclusions, the
so-called myelin figures and zebra bodies, in different organs
and cell types.1,2 Progressive cardiovascular, neurological, and
renal complications are hallmarks of the disease, all potentially
fatal.3,4 Most males and up to 15–20% of female Fabry patients
eventually develop severe or end-stage renal disease,5 and
overt proteinuria is a finding in nearly all these patients.6
Proteinuria, which is long considered the first clinical
manifestation of Fabry nephropathy, may start as early as at
10 years of age.7 Recent morphologic studies have demon-
strated that nephropathy may be prominent even before
clinical signs of renal disease become apparent.8,9 Once overt
proteinuria is established, glomerular filtration rate (GFR)
declines inexorably toward end-stage renal disease, often by
the third to fifth decade of life in males,10 and rarely, as early as
16 years of age.7 Enzyme replacement therapy (ERT), if started
early, may yet be proven to prevent subsequent vital organ
damage.11,12 However, once proteinuria is manifest, respon-
siveness to ERTmay be incomplete, and proteinuria generally
does not normalize.13,14 There are no clear genotype and
phenotype correlations, and disease progression is variable
among individuals. Moreover, there are no clear guidelines for
initiation of ERT in young Fabry patients.
Only few studies focus on early renal pathologic lesions of
Fabry disease.8,15 Such studies, including re-biopsy studies
after several years of ERT, are necessary for the discovery of
early morphologic biomarkers of disease progression, which
could be used as potential prognostic tools and treatment
guides. We have developed unbiased stereological methods to
study early glomerular electron microscopic (EM) changes of
nephropathy in young Fabry patients and, for the first time,
have shown relationships between these structural changes
and urinary protein excretion in Fabry patients.
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RESULTS
The demographical and clinical characteristics of Fabry
patients are summarized in Table 1. Male and female patients
were not statistically different in age (Table 2). However, the
control subjects were older than the Fabry patients
(P¼ 0.0005). Six patients (M/F¼ 3/3) had detectable (40)
urine protein values (urine protein/creatinine ratios
11–251mg/g or 1.2–28mg/mmol). Serum creatinine was
normal in all patients where determined (n¼ 10). Four
patients with no serum creatinine values had normal blood
urea nitrogen values (Table 1). Measured (n¼ 8) and
estimated (n¼ 2) GFR ranged from 90 to 183 (median
106) ml/min per 1.73m2. Urinary protein excretion and GFR
were not statistically different between male and female Fabry
patients. There was a direct relationship between urinary
protein excretion rate and age (r¼ 0.65, P¼ 0.01).
GL-3 inclusions were present in all glomerular cell types,
and were most abundant in podocytes (Figure 1). These
inclusions, although sharing multilamellation and electron
density, varied in size and shape. Generally, inclusions within
mesangial cells were the smallest and within podocytes were
the largest. The volume fraction of GL-3 inclusions per
podocyte (Vv(Inc/PC)) increased with age, as did podocyte
foot process width (FPW), whereas there was no significant
relationship between age and the volume fraction of GL-3
inclusions per endothelial cell (Vv(Inc/Endo)) or per
mesangial cell (Vv(Inc/Mes)) (Figure 2). Vv(Inc/PC) corre-
lated directly with proteinuria (r¼ 0.76, P¼ 0.001; Figure 3)
and FPW (r¼ 0.71, P¼ 0.005). Segmental foot process
effacement was present in all glomeruli. Detachment of
podocytes from the glomerular basement membrane (GBM)
was very rare or absent in most glomeruli (data not shown).
Table 2 | Demographic, renal functional, and glomerular structural parameters of Fabry patients and controls
Fabry males
(n=8)
Fabry females
(n=6)
Fabry total
(n=14)
Controls (M/F=6/3)
(n=9) P-value
Age (years) 14 (4–19) 12 (8–14) 12 (4–19) 32 (16–52) 0.0005a, 0.0008b, 0.0009c
UPCR (mg/g) 72±81 25±24 52±66 NA NSd
Serum Cr (mg/dl) 0.70±0.15 (n=6) 0.63±0.12 (n=5) 0.65±0.13 (n=11) NA NSd
GFR (ml/min per 1.73m2) 120±37 (n=5) 101±8 (n=5) 111±27 (n=10) NA NSd
Vv(Inc/PC) 0.37±0.11 0.26±0.06 0.32±0.11 — 0.06
d
Vv(Inc/Endo) 0.19±0.12 0.03±0.03 0.12±0.12 — 0.008
d
Vv(Inc/Mes) 0.08±0.06 0.03±0.03 0.06±0.05 — 0.06
d
FPW (nm) 558±133 455±67 514±118 430±61 0.06a, 0.06d, 0.01c
Percent endothelial fenestration 48±14 49±9 48±12 61±9 0.01d, 0.06a, 0.03c
Abbreviations: FPW, foot process width; GFR, glomerular filtration rate; GL-3, globotriaosylceramide; ND, not detectable per historical records; NA, not available; S/Cr, serum
creatinine; UPCR, urinary protein/creatinine ratio; Vv(Inc/Endo), fractional volume of endothelial cell GL-3 inclusions per cytoplasm; Vv(Inc/Mes), mesangial cell GL-3 inclusions
per cytoplasm; Vv(Inc/PC), fractional volume of podocyte GL-3 inclusions per cytoplasm.
aFemale Fabry vs control.
bMale Fabry vs control.
cMale vs female Fabry.
dCombined male and female Fabry vs control.
All values are mean±s.d. except for age and UPCR that are median (range). To convert UPCR from mg/g to mg/mmol, multiply by 0.113 (which are median (range)).
Table 1 | Demographic and clinical characteristics of Fabry patients
Patient no. Sex
Age
(year) Angiokeratoma
Acroparesthesia/
pain
Corneal
opacity
UPCR
(mg/g)
S/Cr
(mg/dl) GFR
1 M 4    0 0.5 490a
2 M 7    0 0.49 183b
3 F 8 + + + 41d NA NA
4 F 9  +  19 0.59 106b
5 M 11 + + + 39d NA NA
6 F 11  + + o0.015 (g/dl) 0.51 105b
7 M 12 + + + 39d NA NA
8 F 12  +  29 0.69 109b
9 F 13  + + 0 0.81 97b
10 F 14  + + 62 0.57 90b
11 M 15 + + + 0.1–0.6 (g/day) 0.75 NA
12 M 16 + + + 92 0.72 112b
13 M 18 + + + 251 0.87 96b
14 M 19 + + + 50d 0.6 120c
Abbreviations: GFR, glomerular filtration rate; NA, not available S/Cr or GFR, but blood urea nitrogen value was normal; ND, not detectable per historical records; S/Cr, serum
creatinine; UPCR, urinary protein/creatinine ratio.
GFR values are based on clearances of
acystatin C,
biohexol, or
ccreatinine.
dAverage normal UPCR for age from Houser et al.36 Patients (1 and 2), (3 and 7), and (4 and 8) are siblings.
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There was a trend for greater FPW in the total Fabry cohort
than in control subjects (P¼ 0.06, Table 2).
Vv(Inc/Endo) was greater in male vs female patients
(P¼ 0.008, Table 2). There were trends for greater
Vv(Inc/PC) (P¼ 0.06) and Vv(Inc/Mes) (P¼ 0.06) in males
vs females (Table 2). FPW was greater in male patients vs
control subjects (P¼ 0.01, Table 2), whereas there was no
statistically significant difference in FPW between control
subjects and female patients. There was a trend for greater
FPW in male vs female Fabry patients (P¼ 0.06, Table 2).
FPW correlated directly with proteinuria (r¼ 0.81,
P¼ 0.0001; Figure 3). Vv(Inc/Mes) also correlated directly
with Vv(Inc/PC) (r¼ 0.61,P¼ 0.02), FPW (r¼ 0.70,
P¼ 0.006), and proteinuria (r¼ 0.68, P¼ 0.008; Figure 3).
However, there was no relationship between Vv(Inc/Endo)
and proteinuria. There was a direct relationship between
Vv(Inc/Mes) and Vv(Inc/Endo) (r¼ 0.76, P¼ 0.002). There
was a trend for a direct correlation between Vv(Inc/PC) and
Vv(Inc/Endo) (r¼ 0.52, P¼ 0.06). Glomerular endothelial
fenestration was reduced in Fabry patients compared with
controls (P¼ 0.01, Table 2); this was statistically significant in
male patients (P¼ 0.03) but only a trend in female patients
(P¼ 0.06). However, there was no statistically significant
difference in glomerular endothelial fenestration between
male and female Fabry patients. Although the number of
cases was limited, there was no trend for a relationship
between age and FPW or endothelial fenestration in the
controls, nor was there a trend for these parameters to be
different between male and female controls. There was no
relationship between percent endothelial fenestration and
Vv(Inc/Endo), age, proteinuria, or GFR. Vv(Inc/Endo) was
greater in male vs female patients (P¼ 0.008, Table 2).
DISCUSSION
This is the first study of glomerular ultrastructural lesions
of Fabry nephropathy using unbiased stereological quanti-
tative methods. Furthermore, it is the first study showing
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Figure 2 |Relationship between age and podocyte (Vv(Inc/PC)), mesangial (Vv(Inc/Mes)), and endothelial cell (Vv(Inc/Endo))
globotriaosylceramide (GL-3) fractional volume of inclusions per cytoplasm and foot process width (FPW) in Fabry patients.
(K represents male and J female; the bold line is the regression line and the dashed lines are 95% confidence interval boundaries).
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Figure 1 |Globotriaosylceramide (GL-3) inclusions in
glomerular podocytes (arrowhead), endothelial cells (double
arrowhead), and mesangial cells (spiral arrow) from the
kidney biopsy of a Fabry patient (TEM  11,000).
C, capillary lumen; E, endothelial cell; GBM, glomerular basement
membrane; M, mesangium; PC, podocyte; TEM, transmission
electron microscopy.
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age-dependent progressive accumulation of GL-3 deposits in
podocytes in a cohort of young Fabry patients with normal
GFR with absent or low-grade proteinuria. Although
angiokeratoma corporis diffusum was first described by
Fabry in 1898,16 Fabry renal pathology was only recognized
approximately half a century later by Pompen et al.17 when
reporting autopsies of three brothers. More detailed descrip-
tions, including biopsies from children with Fabry disease,
were published later by Gubler et al.15 and Desbois et al.18 In
fact, GL-3 inclusions have been described in kidney cells,
especially in podocytes, as well as in heart, cornea, and
placenta in the autopsies of Fabry disease fetuses.19–21
Concordant with previous studies,8,15 we identified GL-3
inclusions in all glomerular cell types (podocytes and
endothelial and mesangial cells) in our young Fabry patients,
including a 4-year-old boy.
In a classic paper of Fabry renal pathology, Gubler et al.15
used a semiquantitative scoring system for intracellular GL-3
inclusions. These authors did not find significant relation-
ships between inclusions in any glomerular cells and age,15
nor did this study detect variations in podocyte GL-3 scores
among the patients. Tøndel et al.8 described renal lesions in 9
Fabry children aged 7–18 years with normal GFR values,
but with slightly elevated urine albumin in 2/3 of patients.
Using a light microscopic semiquantitative method, the
scores for GL-3 inclusions in podocytes were virtually
identical in all biopsies in this study. No statistically
significant relationships were found between inclusion scores
in different cell types and age, GFR, or proteinuria. Similarly,
a recent light microscopy scoring system for renal lesions
proposed by the ISGFN (International Study Group of
Fabry Nephropathy) did not identify relationships between
cellular inclusion scores and renal function.9 However,
most cases in this latter study were adult Fabry patients
with mild nephropathy (chronic kidney disease stages 1
and 2).
In contrast, the present study of children and adolescents
utilizing quantitative stereological EM methods documented
progressive accumulation of podocyte GL-3 inclusions with
increasing age. This is likely because of greater precision and
perhaps accuracy in EM stereological methods to estimate
cellular GL-3 accumulation. Similar to these earlier stu-
dies,8,15 we found it difficult to appreciate differences in
inclusion densities in podocytes by light microscopy when, in
fact, there was substantial difference by EM stereology (data
not presented). This was, perhaps, especially true for
endothelial and mesangial inclusions, which are less abun-
dant and usually smaller than those in podocytes where EM
appears to provide even greater precision and sensitivity
(data not presented). Systematic uniform random sampling
is, in fact, an efficient tool to study variable, but not rare,
phenomena in biology.22 This sampling is designed to
overcome variations in sampling (glomeruli, sections,
microscopic fields, and so on) efficiently and, in an unbiased
way, to unveil the true biologic variation that underlies
relationships between parameters, and difference among
groups. The methods used in the present studies provide
mean values of GL-3 inclusion densities among the sampled
cell types. These methods are not suitable to distinguish
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Figure 3 |Relationships between urinary protein/creatinine
ratio (UPCR, mg/g) and foot process width (FPW, nm),
globotriaosylceramide (GL-3) inclusion fractional volume per
podocyte cytoplasm (Vv(Inc/PC)), and mesangial cell
cytoplasm (Vv(Inc/Mes)) in Fabry patients. (K represents male
and J female; the bold line is the regression line and the dashed
lines are 95% confidence interval boundaries).
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between uniform vs heterogeneous distributions of cellular
GL-3 inclusion densities. The latter, perhaps, might be
posited as an expression of lionization in females.
The progressive accumulation of GL-3 inclusions with age
in podocytes and not in the endothelial or mesangial cells
may result from different rates of GL-3 production in these
different cell types. This may also reflect the rate at which
these cells turn over. In contrast to endothelial and mesangial
cells, podocytes are thought to be terminally differentiated
and to proliferate poorly in response to injury or loss.23
Podocyte loss is associated with segmental, and eventually
global glomerulosclerosis,24 the common findings in advan-
ced Fabry nephropathy. Increase in FPW, an indicator of
podocyte injury, was greater in young male compared with
female Fabry patients and with normal subjects in the present
study. Tøndel et al.8 observed qualitative segmental foot
process effacement in all young Fabry patients in their study,
despite albumin excretion rate within the so-called ‘nor-
moalbuminuric’ range in some of those patients. In fact,
albumin excretion rate in normal children of similar age is
much lower than 20 mg/min, the upper limit for ‘normoal-
buminuria’ that is conventionally accepted.25 Moreover,
increased leakage of albumin and other proteins across the
glomerular filtration barrier may not be detectable in the
final urine unless it surpasses tubular reabsorption capacity.
Torbjo¨rnsdotter et al.26 documented increased FPW in
‘normoalbuminuric’ young type 1 diabetic patients compared
with normal living kidney donors. The presence of podocyte
injury in normoalbuminuric young Fabry patients in the
present study suggests that albuminuria/proteinuria is not
sensitive enough to detect early kidney injury in Fabry
nephropathy. Thus, our findings further strengthen previous
observations that clinical parameters alone do not permit a
diagnosis of early Fabry nephropathy, but this can be made
based on renal biopsy.8,9 In addition, renal biopsy is also a
useful tool to exclude non-Fabry renal diseases in cases with
atypical clinical course, such as rapid decline of renal
function or very early development of heavy proteinuria.
Importantly, this study is the first to find strong relation-
ships between early structural and early functional changes in
Fabry renal disease. FPW and the fractional volume of GL-3
inclusions in the podocytes correlated with urinary protein
excretion rates. ERT leads to a rapid and marked decrease in
mesangial and endothelial cell GL-3 inclusions, whereas
podocyte inclusions and proteinuria persist despite this
treatment.27–29 This argues that podocyte inclusions may be
of greater pathogenic importance to proteinuria than the
mesangial and endothelial cell inclusions. Further support for
this thesis comes from the correlation between FPW and
proteinuria in Fabry patients, especially in males, and from
the correlation of FPW and the fractional volume podocyte
inclusions. Nevertheless, endothelial and vascular lesions may
still be important in the pathogenesis of renal or extrarenal
complications of Fabry disease. We also found a direct
relationship between mesangial cell GL-3 inclusion densities,
proteinuria, and FPW, and this deserves further investigation.
As progression of proteinuria, especially to levels exceed-
ing 1 g per 24 h, is a strong predictor of progression to
end-stage renal disease in Fabry disease,27,30 these early
structural–functional relationships in Fabry nephropathy are
likely to be clinically significant. If, as we suspect, it can be
established that robust quantitative stereological early
measures of structural parameters are predictive of disease
progression, then renal biopsy could become an additional
tool in Fabry disease prognosis and management, at least
until noninvasive biomarkers come along. Such structural
predictors could potentially also be used as end points for
clinical trials. The validity of these speculations remains to be
determined in future studies.
This study included a limited number of female Fabry
patients with proteinuria data, and thus, comparison of these
values between the sexes may not be statistically informative;
however, FPW was greater in boys. There were also trends for
less GL-3 inclusions in podocytes and mesangial cells in girls.
This gender difference was particularly striking for GL-3
inclusions in endothelial cells (about 6 times less in females).
Perhaps residual levels of enzyme activity could explain the
lesser GL-3 accumulation in these cells in females.
GL-3 inclusion density in endothelial and in mesangial
cells did not progress with age in either sex in this study.
Moreover, as noted above, ERT rapidly reduces inclusions in
endothelial and mesangial cells, whereas in patients with
proteinuria, the disease may progress.11,31 Thus, endothelial
or mesangial GL-3 inclusion density are probably not the best
primary end points for clinical trials in Fabry disease.
Endothelial fenestration was reduced in Fabry patients, a
finding similar to that we reported in diabetic nephropathy.32
This could reflect endothelial injury and dysfunction and
goes along with findings of reduced nitric oxide bioavail-
ability in endothelial cells of a mouse model of Fabry
disease.33
Our study has some limitations. Although this is the
largest biopsy study in young Fabry patients, a larger number
of patients might have improved our ability to find certain
relationships or group differences. Control subjects were
older than Fabry patients in this study. As previous studies
suggested important glomerular structural differences (inclu-
ding podocyte FPW) between cadaver and living kidney
donor biopsies,26,34 we confined our studies to living donor
control subjects. This naturally excluded younger children.
Nevertheless, we know of no previous reports suggesting a
change in FPW or endothelial fenestration with age in
humans, nor did we find such trends among our control
subjects.
In summary, this is the first study to show relationships
between proteinuria and early glomerular lesions of Fabry
nephropathy in young patients. Longitudinal studies are
required to establish the predictive value of these early
changes for the ultimate progression of Fabry renal disease.
However, the very long natural history of Fabry nephropathy
makes such studies difficult to do. However, cross-sectional
studies at various stages of the disease could be equally
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informative, as has been the case in diabetic nephropathy.35
Therefore, additional structural–functional relationship
studies at later stages of the disease are required to better
understand the progression of these and other structural
parameters in relation to important clinical outcomes,
such as GFR loss and end-stage renal disease. Nevertheless,
the relationships between early structural changes and
proteinuria presented here suggest that such studies would
prove useful.
MATERIALS AND METHODS
Subjects
Renal biopsies from 14 (M/F¼ 8/6) ERT-naive Fabry patients
(12 (4–19)) years old) were studied by EM stereology. Nine
(M/F¼ 6/3) normal living kidney donors served as control
subjects. Four Fabry biopsies (from Hoˆpital Necker, Paris,
France) were archived materials with limited available clinical
information. Per medical records, these biopsies were from
patients with no proteinuria. Average normal urine protein/
creatinine ratio values for age were used in statistical analyses
for these subjects.36 Recent biopsies were all performed
shortly before initiation of ERT and after informed consent
was obtained. Both the Norwegian cases and the Minneapolis
cases had renal biopsies in order to obtain a baseline
evaluation and to make decisions regarding the initiation of
ERT. These patients also had clinical symptoms qualifying
them for ERT. Protein excretion per gram creatinine was
derived from urines obtained close to the date of biopsy. GFR
was estimated by the plasma clearance of iohexol (n¼ 8) or
creatinine (n¼ 1), or by cystatin C (n¼ 1) levels.
Stereological methods
Semithin (1mm) toluidine blue stained sections were
prepared from resin-embedded biopsy tissues. The center-
most glomerulus with intact Bowman’s capsule and no
discernible mechanical artifact in each EM block was selected.
Between 1 and 5 glomeruli per biopsy were studied. Thin
(60–90 nm) sections were mounted on Formvar-coated slot
cupper grids. Digital EM images were taken by a JEOL 100CX
TEM (JEOL, Tokyo, Japan) according to a systematic
uniform random sampling protocol at 16,000 and 35,000
magnifications. Volume fraction of GL-3 inclusions in
podocytes (Vv(Inc/PC)), and endothelial (Vv(Inc/Endo))
and mesangial cell cytoplasm (Vv(Inc/Mes)) were estimated
on  16,000 images using a point counting method using
grids with the following characteristics: Vv(Inc/PC), points
60mm apart; Vv(Inc/Endo), points 40mm apart and 4 fine
points per each course point; and Vv(Inc/Mes), coarse points
60mm apart and 9 fine points per each coarse point. The
following equations were used to estimate these parameters:
VVðInc=PCÞ ¼
P
FPInc
P
FPPC
; VVðInc=EndoÞ ¼
P
FPInc
4:
P
CPEndo
; and
VVðInc=MesÞ ¼
P
FPInc
9:
P
CPMes
, where FP¼ fine points; CP¼
coarse points, Inc¼ inclusions; PC¼ podocyte cytoplasm;
Endo¼ endothelial cytoplasm; and Mes¼mesangial cyto-
plasm. A line drawn where the GBM and capillary lumina lost
their parallelism was used to define peripheral vs mesangial
components of GBM and capillary lumenal surface. FPW was
estimated as the reciprocal of filtration slit length density
[Ls(SP/GBM)] on peripheral GBM on 35,000 images 32.
Percent endothelial fenestration on the peripheral capillary
lumenal surface was estimated on the same images using a
line intercept counting method. In brief, an unbiased
counting frame (224 224mm) with fine parallel lines
4mm apart and one course line per 7 fine lines was
superimposed on these images (Figure 4). The intercept of
each coarse line with capillary lumenal surface was
considered non-fenestrated if the distance between the two
fenestrae on each side of the coarse line was more than three
fine lines, and otherwise it was called fenestrated (Figure 5).
Percent endothelial fenestration was calculated as
P
Ifenestrated
P
Itotal
,
where I is the number of grid coarse line intercepts with
fenestrated (numerator) or total (denominator) peripheral
capillary endothelial coverage.
Figure 4 |The grid used to estimate percent endothelial
fenestration composed of an unbiased counting frame with
inclusion (dashed) and exclusion (continuous) borders, and
parallel lines 4mm apart. There is one coarse line (where the
intercepts with endothelial coverage are counted) per seven fine
lines. The short lines on the coarse lines are 4mm apart and,
similar to fine lines, are used to define fenestrated vs non-
fenestrated coverage. The endothelial coverage was arbitrarily
called non-fenestrated if the distance between the two fenestrae
on either side of the coarse line was more than 3 fine and coarse
lines, and otherwise it was called fenestrated.
668 Kidney International (2011) 79, 663–670
or ig ina l a r t i c l e B Najafian et al.: Quantitation of podocyte GL-3 in Fabry disease
Statistics
Data are presented as mean±s.d., except for age and urinary
protein excretion that are presented as median (range).
Unpaired two-tailed Student’s t-test or analysis of variance
with least square distance post hoc test was performed for
group comparisons. Linear regression analyses were per-
formed for intervariable relationships. The P-values ofo0.05
were considered to be significant.
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